MedPath

Study With Vortioxetine on Emotional Functioning in Patients With Depressio

Phase 1
Conditions
Emotional functioning in patients with MDD
MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disorders
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2017-004829-33-LT
Lead Sponsor
H. Lundbeck A/S
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

The patient has a primary diagnosis of single or recurrent MDD according
to DSM-5®. The current major depressive episode (MDE) must be
confirmed using the Mini International Neuropsychiatric Interview (MINI).
• The patient has had the current MDE for <12 months.
• The patient has a Montgomery and Åsberg Depression Rating Scale
(MADRS) total score = 22 and = 28 at the Baseline Visit.
• The patient has been treated with SSRI/SNRI monotherapy (citalopram,
escitalopram, paroxetine, sertraline, duloxetine or venlafaxine) for at least 6 weeks at
adequate dose for the current MDE and with an inadequate response and
is a candidate for a switch in the investigator’s opinion.
• The patient wants to switch antidepressant treatment.
• The patient has an ODQ total score =50 at baseline, while on SSRI/SNRI
monotherapy (prior to switch).
• The patient answered Yes to the screening question on emotional effects.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 150
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

The patient has a significant risk of suicide according to the investigator’s
clinical judgment or has made an actual suicide attempt in the previous 6
months prior to Baseline

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath